Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Keyphrases

• Acute Lymphoblastic Leukemia 100%
• Acute Lymphoblastic Leukemia Cells 33%
• Clinical Setting 33%
• Early Clinical Development 33%
• Effective Treatment 33%
• Heat Shock Protein 90 (Hsp90) 100%
• Heat Shock Protein 90 Inhibitor 33%
• Inhibitor Therapy 33%
• JAK Inhibition 33%
• JAK Inhibitors 33%
• JAK Kinases 33%
• Janus Kinase 2 (JAK2) 33%
• Limited Ability 33%
• Malignancy 33%
• Purine Scaffold 33%
• Ruxolitinib 66%
• Specific Heat 100%
• Therapeutic Approaches 100%
• Tumor-specific 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Lymphoblastic Leukemia 100%
• Heat Shock Protein 90 100%
• Heat Shock Protein 90 Inhibitor 25%
• Janus Kinase 1 25%
• Janus Kinase Inhibitor 25%
• Neoplasm 100%
• Phosphotransferase 25%
• Purine 25%
• Ruxolitinib 50%

Biochemistry, Genetics and Molecular Biology

• Heat Shock Protein 100%
• Heat Shock Protein 90 Inhibitor 50%
• Janus Kinase 1 50%
• Janus Kinase Inhibitor 50%
• Kinase 50%
• Phosphotransferase 50%
• Ruxolitinib 100%